COSTEM 2022 | The role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
Nico Gagelmann
• 28 Oct 2022
Patients with myelofibrosis (MF) who have thrombocytopenia prior to transplant have been shown to have inferior outcomes when compared to other patients. In this video, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, describes treatment strategies for patients with MF and thrombocytopenia. Pacritinib, a JAK inhibitor, is being explored as a potential bridging therapy for this group of patients. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
